14 research outputs found

    Incidence of EAEC.

    No full text
    <p>Cumulative incidence of first EAEC detection in A) surveillance and diarrheal stools at all sites and B) surveillance stools by site among 2,092 children with at least one stool sample in the MAL-ED birth cohort. BGD–Dhaka, Bangladesh; BRF–Fortaleza, Brazil; INV–Vellore, India; NEB–Bhaktapur, Nepal; PEL–Loreto, Peru; PKN–Naushahro Feroze, Pakistan; SAV–Venda, South Africa; TZH–Haydom, Tanzania.</p

    Long-term growth.

    No full text
    <p>Adjusted site-specific association between EAEC detection in monthly surveillance stools and A: weight-for-age z-score (WAZ) and B: length-for-age z-score (LAZ) at two years of age among 1,727 children in the MAL-ED cohort who had anthropometric measurements at two years. Estimates are the z-score difference associated with a high frequency of EAEC detection compared to a low frequency of EAEC detection. Definitions for high and low frequency are based on the 10<sup>th</sup> and 90<sup>th</sup> percentiles of stool positivity in the cohort. Low: ≤11% of surveillance stools positive for EAEC; high: ≥50% of surveillance stools positive for EAEC.</p

    Short-term growth.

    No full text
    <p>Adjusted site-specific associations between EAEC detection in monthly surveillance stools and A) weight-for-age z-score (WAZ) velocity and B) length-for-age z-score (LAZ) velocity over the subsequent month among 2,050 children in the MAL-ED cohort with at least one surveillance stool and at least one month of complete anthropometric measurements and testing for EAEC and <i>Campylobacter</i>.</p

    Fecal MPO, Fecal alpha-1-antitrypsin (A1AT), and plasma LPS, FABP and SAA each predicts subsequent growth impairment.

    No full text
    <p>a: For MPO, <i>p</i> = 0.028; n = 266 when correcting for age and gender, and independent of breastfeeding status (that showed no correlation in these 6-26m old children) and of age. b: For A1AT, n = 237; <i>p</i> = 0.042; and A1AT also correlates with “catchup WAZ” as well, <i>p</i> = 0.035 after correcting for age and gender. c: For urine L/M, higher values correlated (controlling for age and gender) with impaired growth (delta HAZ) (<i>r</i> = -0.173; <i>p</i> = 0.009; n = 230). d: For plasma LPS (ie lower LUM), higher values correlated with impaired growth (delta HAZ) (<i>r</i> = 0.151; <i>p</i> = 0.017; n = 251). e: For plasma FABP, higher values correlated with impaired growth (delta HAZ) (r = -0.134; <i>p</i> = 0.042; n = 231). f: For plasma SAA, higher values correlated with impaired growth (delta HAZ) (r = -0.132; p = 0.046; n = 231).</p
    corecore